Cost Analysis of Biosimilars

Biologics are complex, protein-based drugs including insulin, monoclonal antibodies to block inflammation in rheumatoid arthritis, and a range of drugs to treat cancer, multiple sclerosis, and other serious diseases. While biologics have revolutionized treatment for many conditions, they are often expensive in terms of cost per dose. The introduction of biosimilars is expected to reduce prices, albeit to a lesser degree, comparable to small-molecule generics.

  • Pharmacoeconomic Modelling of Biosimilars
  • Risk management plan (RMP) for Biosimilars
  • Cost minimal analysis
  • Cost benefit analysis
  • Cost effectiveness analysis
  • Cost utility analysis
  • Quality adjusted life years

Related Conference of Cost Analysis of Biosimilars

August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan
August 29-30, 2018 |

International Conference and Exhibition on Drug Safety & Pharmacovigilance

Park Inn By Radisson Toronto Airport West, 175 Derry Road East, Mississauga, ON, L5T 2Z7, Canada
October 18-20, 2018

18th World Pharma Congress

Warsaw, Poland
November 14-15 | 2018

13th International Conference on Biosimilars and Biologics

Lisbon | Portugal
September 18-19, 2018

6 th European Biopharma Congress

Amsterdam, Netherlands

Cost Analysis of Biosimilars Conference Speakers

Recommended Sessions

Related Journals

Are you interested in